Subscribe
Ivan Marc / Shutterstock.com
2 October 2025NewsAmericasMarisa Woutersen

IP agencies vital to pharma and biotech grind to a halt

From stalled drug approvals to suspended patent investigations, US rightsholders face mounting uncertainty during the federal freeze. 

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Trump threatens 100% tariff hike on pharma imports into the US
26 September 2025   Sweeping tariffs send shockwaves through the pharma sector, as experts warn of consumer detriment and supply chain risks.
Americas
Trump’s march-in rights threat: Why pharma is rethinking university deals
9 September 2025   Federal oversight, funding cuts, and patent uncertainties are forcing universities, startups, and pharma companies to reassess partnership models, finds Marisa Woutersen.
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025   Return-to-office orders, redundancies, hiring freezes—do changes sweeping through the US agency ‘risk breaking the system’? Marisa Woutersen finds patent practitioners fearful of the future.


Editor's picks

Why AI is changing the patent rules faster than anyone can keep up
Americas
Why AI is changing the patent rules faster than anyone can keep up
24 October 2025

Editor's picks

Americas
Why AI is changing the patent rules faster than anyone can keep up
24 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025
Americas
Top pharma, biotech, and medtech experts gather at LSPN Fall
21 October 2025
Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025
Americas
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
13 October 2025

More features

‘We're being attacked from all sides’: Thermo Fisher Scientific counsel
China trademarks rankings reveal new entries, hidden gems and big brands
Edwards defends key heart valve product from infringement threat
Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?
The hidden code in life sciences deals
Why AI is changing the patent rules faster than anyone can keep up
LSPN panel unpacks critical IP risks in deal-making
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order